Ocampo will expand research to advance WoundVision’s position as the leader in pressure injury prevention, POA ...
Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta. Follicular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results